[Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
In order to determine whether the lipid-lowering effect of combined treatment with clofibrate and beta-Pyridylcarbinol exceeds that of clofibrate monotherapy, a double-blind crossover study was performed. 17 patients with primary hyperlipoproteinemia of Type IIa and 10 patients with primary hyperlipoproteinemia of Type IIb received either Lipofacton (1.000 mg clofibrate and 50 mg beta-pyridylcarbinol per day) or clofibrate (1.500 mg per day) for a period of 6 weeks each. Before beginning therapy and between both periods of medication, placebo was administered for 14 days. In both total plasma and in the LDL fraction the cholesterol level was lowered by less than 10% for both substances. In patients with hyperlipoproteinemia of Type IIb, the triglyceride levels were lowered by about 40%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009540:Nicotinyl Alcohol / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D004338:Drug Combinations; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011725:Pyridines; D014280:Triglycerides; D002784:Cholesterol; D009540:Nicotinyl Alcohol; D002994:Clofibrate
Kombination Clofibrat/beta-Pyridylcarbinol und Monotherapie mit Clofibrat.